SENATE-BILL 1407: S.1407 - ABC Safe Drug Act
AI-Powered Summary
SENATE-BILL 1407 aims to restrict federal health programs from purchasing drugs manufactured in China, thereby impacting the availability and cost of medications for individuals reliant on these programs. Major themes include healthcare access, constitutional rights, and economic implications for the pharmaceutical industry. Key provisions mandate that starting from 2028 and 2030, federal health programs can only procure drugs with active ingredients sourced from countries other than China, with the Secretary of Health and Human Services empowered to issue waivers for compliance challenges. Additionally, the bill introduces a temporary provision for 100% expensing of pharmaceutical manufacturing property. The implementation timeline is set for gradual enforcement, with significant potential impacts including restricted access to affordable medications, increased costs for individuals, and constitutional concerns regarding discrimination and due process rights. The legislation raises questions about the balance between national interests and individual healthcare rights.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
SENATE-BILL 1407 poses significant constitutional implications, particularly regarding access to essential medications for individuals dependent on federal health programs. The potential for increased costs and reduced availability of medications could exacerbate health disparities among various demographic groups.
Key Individual Rights Affected
- Equal Protection under the 14th Amendment
- Implied Right to Health Care
- Access to Medications
Constitutional Provisions
- 14th Amendment - Equal Protection Clause
- Commerce Clause
Potential Constitutional Challenges
The bill may face legal challenges based on equal protection claims, particularly if it is shown to disproportionately harm low-income individuals, seniors, and those with disabilities. Additionally, arguments may arise regarding the government's responsibility to ensure access to essential health services.
Summary
The 'Anyone But China Safe Drug Act' seeks to limit federal funding for pharmaceuticals from China, which could lead to higher drug prices and reduced access for vulnerable populations. This raises significant constitutional concerns regarding equal protection and access to health care, particularly for those reliant on federal programs. The implications of this bill necessitate careful consideration of its impact on individual rights and health equity.
Constitutional Analysis
This bill has been analyzed for constitutional compliance using AI-powered analysis of constitutional principles and precedents.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention S. 1407 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
April 10, 2025
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat